Chinese flying taxi maker EHang rejects US short seller’s fraud accusations over firm’s 1,300-unit pre-orders
- EHang blamed the short seller’s ‘cursory and incomplete understanding’ of its industry for a report that contained ‘misinterpretation of information’
- Hindenburg Research claimed that most of EHang’s over 1,300-unit pre-orders are based on ‘dead’ or ‘abandoned’ deals and failed partnerships
EHang blamed the short seller’s “cursory and incomplete understanding” of its industry for a report that contained “untrue statements and misinterpretation of information” about the firm’s operations and financial condition, according to the Nasdaq-listed company’s statement on Tuesday, the same day Hindenburg Research published its findings.
The short seller’s report claimed that more than 92 per cent of EHang’s pre-order book, totalling over 1,300 units, are based on “dead” or “abandoned” deals, failed partnerships and newly formed customer entities with no discernible operations.
EHang’s largest deal is a 1,000-unit pre-order from one of its pre-initial public offering investors, a biotech company called United Therapeutics, which represents about 74 per cent of the Chinese passenger drone maker’s total pre-orders, according to the report. The deal was initially signed in 2016.
In response, EHang’s statement asserted that the company’s orders are “based on signed contracts and [are] planned for delivery after obtaining regulatory approvals”.
The orders also showed “strong interest and genuine demand” in the market for its electric vertical take-off and landing (eVTOL) vehicles, EHang said. Without elaborating, it indicated that “appropriate actions’ will be taken to protect the interests of the company and its shareholders.